Humanin多肽类似物的新用途
By constructing a model of intrauterine adhesions and exogenously supplementing with the humanin peptide analog HNG, the problems of fibrosis and re-adhesion after intrauterine adhesion surgery were solved, achieving endometrial repair and improved fertility, and providing a new direction for drug treatment.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- FIRST AFFILIATED HOSPITAL OF KUNMING MEDICAL UNIV
- Filing Date
- 2022-11-15
- Publication Date
- 2026-07-17
AI Technical Summary
In the treatment of intrauterine adhesions (IUA), the regenerative and repair functions of adhesions are severely impaired after surgery. The problem that existing technologies cannot effectively solve is how to construct the regenerative repair and functional impairment of intrauterine adhesions through the dual damage method of mechanical and infectious methods. The problem that existing technologies cannot effectively solve is the formation of fibrosis and re-adhesion after intrauterine adhesion (IUA) surgery, which leads to incomplete endometrial repair and affects fertility.
Using the humanin peptide analog HNG, an SD rat IUA model was constructed through a dual mechanical and infectious injury method. Exogenous HNG supplementation was performed. The novel applications of HNG were evaluated by H&E staining, the morphological changes of the endometrium were assessed by H&E staining, the novel applications of HNG were evaluated by Masson staining, the repair effect of HNG on rat endometrium was assessed by H&E staining, the improvement effect of HNG on rat endometrial fibrosis was assessed by Masson staining, and reproductive experiments were conducted to observe fertility.
The peptide HNG significantly improved uterine fibrosis in rats, increased endometrial thickness and glandular number, reduced fibrotic area, and improved fertility, providing a new drug target for the prevention and treatment of IUA.
Smart Images
Figure CN115838412B_ABST